CANCER RES 润色咨询

CANCER RESEARCH

出版年份：1941 年文章数：12632 投稿命中率： 开通期刊会员，数据随心看

出版周期：Semimonthly 自引率：2.6% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2099486, encodeId=29a3209948625, content=请问各位，最近投稿Cancer research，under review7天了，还没收到外审邮件，大家有遇到过这种情况吗？最长多久会收到外审邮件啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a452506975, createdName=124af5c7m81暂无昵称, createdTime=Wed Nov 09 21:24:07 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094012, encodeId=ba082094012da, content=22.10.06投稿<br>22.10.10Under Review<br>22.1014收到外审邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5f8299982, createdName=ms2000001702708152, createdTime=Sun Oct 16 10:33:47 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤研究<br>经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894681, encodeId=3b5a89468193, content=要不要版面费，这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Tue Oct 27 01:02:14 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001382, encodeId=1e39100138251, content=请问状态变成under review指送外审了吗？但是没有收到送审的邮件通知呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ddd92153968, createdName=1582019d51m, createdTime=Wed Jul 21 13:09:03 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226137, encodeId=de88122613ec4, content=CR内审和外审都是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b48f5153036, createdName=1663238685_12506575, createdTime=Mon Jun 13 11:29:54 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804355, encodeId=335180435555, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：大家好，问个问题：投稿CR后，会显示一个方法上的Score，这个打分对评审文章有用么？大家都打了多少分？有打4分的么？谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:33:18 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211325, encodeId=b9491211325ab, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：1周多点拒稿，还是很难中的！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11e5109668, createdName=tckkhf2006, createdTime=Fri Apr 15 06:21:02 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969493, encodeId=7d30969493ae, content=期刊质量高，认可度很高。有一篇这个去申国自然青年基本稳中，面上也大概率能过函评。和其他8、9分的期刊像oncogene/cancer letter/Theranostics完全不是一个档次的。<br>大家还是争取发这种高质量期刊申基金才有用，现在内卷严重，评委不是吃素的，看到发的都是oncogene/cancer letter/Theranostics这种期刊基本没戏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Sat May 29 18:16:55 CST 2021, time=2021-05-29, status=1, ipAttribution=)]
    2022-11-09 124af5c7m81暂无昵称

    请问各位，最近投稿Cancer research，under review7天了，还没收到外审邮件，大家有遇到过这种情况吗？最长多久会收到外审邮件啊？

    6

    展开6条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2099486, encodeId=29a3209948625, content=请问各位，最近投稿Cancer research，under review7天了，还没收到外审邮件，大家有遇到过这种情况吗？最长多久会收到外审邮件啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a452506975, createdName=124af5c7m81暂无昵称, createdTime=Wed Nov 09 21:24:07 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094012, encodeId=ba082094012da, content=22.10.06投稿<br>22.10.10Under Review<br>22.1014收到外审邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5f8299982, createdName=ms2000001702708152, createdTime=Sun Oct 16 10:33:47 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤研究<br>经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894681, encodeId=3b5a89468193, content=要不要版面费，这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Tue Oct 27 01:02:14 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001382, encodeId=1e39100138251, content=请问状态变成under review指送外审了吗？但是没有收到送审的邮件通知呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ddd92153968, createdName=1582019d51m, createdTime=Wed Jul 21 13:09:03 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226137, encodeId=de88122613ec4, content=CR内审和外审都是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b48f5153036, createdName=1663238685_12506575, createdTime=Mon Jun 13 11:29:54 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804355, encodeId=335180435555, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：大家好，问个问题：投稿CR后，会显示一个方法上的Score，这个打分对评审文章有用么？大家都打了多少分？有打4分的么？谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:33:18 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211325, encodeId=b9491211325ab, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：1周多点拒稿，还是很难中的！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11e5109668, createdName=tckkhf2006, createdTime=Fri Apr 15 06:21:02 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969493, encodeId=7d30969493ae, content=期刊质量高，认可度很高。有一篇这个去申国自然青年基本稳中，面上也大概率能过函评。和其他8、9分的期刊像oncogene/cancer letter/Theranostics完全不是一个档次的。<br>大家还是争取发这种高质量期刊申基金才有用，现在内卷严重，评委不是吃素的，看到发的都是oncogene/cancer letter/Theranostics这种期刊基本没戏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Sat May 29 18:16:55 CST 2021, time=2021-05-29, status=1, ipAttribution=)]
    2022-10-16 ms2000001702708152

    22.10.06投稿
    22.10.10Under Review
    22.1014收到外审邮件

    7

    展开7条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2099486, encodeId=29a3209948625, content=请问各位，最近投稿Cancer research，under review7天了，还没收到外审邮件，大家有遇到过这种情况吗？最长多久会收到外审邮件啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a452506975, createdName=124af5c7m81暂无昵称, createdTime=Wed Nov 09 21:24:07 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094012, encodeId=ba082094012da, content=22.10.06投稿<br>22.10.10Under Review<br>22.1014收到外审邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5f8299982, createdName=ms2000001702708152, createdTime=Sun Oct 16 10:33:47 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤研究<br>经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894681, encodeId=3b5a89468193, content=要不要版面费，这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Tue Oct 27 01:02:14 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001382, encodeId=1e39100138251, content=请问状态变成under review指送外审了吗？但是没有收到送审的邮件通知呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ddd92153968, createdName=1582019d51m, createdTime=Wed Jul 21 13:09:03 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226137, encodeId=de88122613ec4, content=CR内审和外审都是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b48f5153036, createdName=1663238685_12506575, createdTime=Mon Jun 13 11:29:54 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804355, encodeId=335180435555, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：大家好，问个问题：投稿CR后，会显示一个方法上的Score，这个打分对评审文章有用么？大家都打了多少分？有打4分的么？谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:33:18 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211325, encodeId=b9491211325ab, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：1周多点拒稿，还是很难中的！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11e5109668, createdName=tckkhf2006, createdTime=Fri Apr 15 06:21:02 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969493, encodeId=7d30969493ae, content=期刊质量高，认可度很高。有一篇这个去申国自然青年基本稳中，面上也大概率能过函评。和其他8、9分的期刊像oncogene/cancer letter/Theranostics完全不是一个档次的。<br>大家还是争取发这种高质量期刊申基金才有用，现在内卷严重，评委不是吃素的，看到发的都是oncogene/cancer letter/Theranostics这种期刊基本没戏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Sat May 29 18:16:55 CST 2021, time=2021-05-29, status=1, ipAttribution=)]
    2022-11-20 slientwo

    审稿速度:2.0 | 投稿命中率:25.0
    偏重的研究方向：肿瘤研究
    经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2099486, encodeId=29a3209948625, content=请问各位，最近投稿Cancer research，under review7天了，还没收到外审邮件，大家有遇到过这种情况吗？最长多久会收到外审邮件啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a452506975, createdName=124af5c7m81暂无昵称, createdTime=Wed Nov 09 21:24:07 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094012, encodeId=ba082094012da, content=22.10.06投稿<br>22.10.10Under Review<br>22.1014收到外审邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5f8299982, createdName=ms2000001702708152, createdTime=Sun Oct 16 10:33:47 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤研究<br>经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894681, encodeId=3b5a89468193, content=要不要版面费，这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Tue Oct 27 01:02:14 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001382, encodeId=1e39100138251, content=请问状态变成under review指送外审了吗？但是没有收到送审的邮件通知呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ddd92153968, createdName=1582019d51m, createdTime=Wed Jul 21 13:09:03 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226137, encodeId=de88122613ec4, content=CR内审和外审都是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b48f5153036, createdName=1663238685_12506575, createdTime=Mon Jun 13 11:29:54 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804355, encodeId=335180435555, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：大家好，问个问题：投稿CR后，会显示一个方法上的Score，这个打分对评审文章有用么？大家都打了多少分？有打4分的么？谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:33:18 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211325, encodeId=b9491211325ab, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：1周多点拒稿，还是很难中的！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11e5109668, createdName=tckkhf2006, createdTime=Fri Apr 15 06:21:02 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969493, encodeId=7d30969493ae, content=期刊质量高，认可度很高。有一篇这个去申国自然青年基本稳中，面上也大概率能过函评。和其他8、9分的期刊像oncogene/cancer letter/Theranostics完全不是一个档次的。<br>大家还是争取发这种高质量期刊申基金才有用，现在内卷严重，评委不是吃素的，看到发的都是oncogene/cancer letter/Theranostics这种期刊基本没戏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Sat May 29 18:16:55 CST 2021, time=2021-05-29, status=1, ipAttribution=)]
    2020-10-27 Lord Megatron

    要不要版面费，这期刊

    3

    展开3条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2099486, encodeId=29a3209948625, content=请问各位，最近投稿Cancer research，under review7天了，还没收到外审邮件，大家有遇到过这种情况吗？最长多久会收到外审邮件啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a452506975, createdName=124af5c7m81暂无昵称, createdTime=Wed Nov 09 21:24:07 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094012, encodeId=ba082094012da, content=22.10.06投稿<br>22.10.10Under Review<br>22.1014收到外审邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5f8299982, createdName=ms2000001702708152, createdTime=Sun Oct 16 10:33:47 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤研究<br>经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894681, encodeId=3b5a89468193, content=要不要版面费，这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Tue Oct 27 01:02:14 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001382, encodeId=1e39100138251, content=请问状态变成under review指送外审了吗？但是没有收到送审的邮件通知呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ddd92153968, createdName=1582019d51m, createdTime=Wed Jul 21 13:09:03 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226137, encodeId=de88122613ec4, content=CR内审和外审都是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b48f5153036, createdName=1663238685_12506575, createdTime=Mon Jun 13 11:29:54 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804355, encodeId=335180435555, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：大家好，问个问题：投稿CR后，会显示一个方法上的Score，这个打分对评审文章有用么？大家都打了多少分？有打4分的么？谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:33:18 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211325, encodeId=b9491211325ab, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：1周多点拒稿，还是很难中的！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11e5109668, createdName=tckkhf2006, createdTime=Fri Apr 15 06:21:02 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969493, encodeId=7d30969493ae, content=期刊质量高，认可度很高。有一篇这个去申国自然青年基本稳中，面上也大概率能过函评。和其他8、9分的期刊像oncogene/cancer letter/Theranostics完全不是一个档次的。<br>大家还是争取发这种高质量期刊申基金才有用，现在内卷严重，评委不是吃素的，看到发的都是oncogene/cancer letter/Theranostics这种期刊基本没戏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Sat May 29 18:16:55 CST 2021, time=2021-05-29, status=1, ipAttribution=)]
    2021-07-21 1582019d51m

    请问状态变成under review指送外审了吗？但是没有收到送审的邮件通知呢

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2099486, encodeId=29a3209948625, content=请问各位，最近投稿Cancer research，under review7天了，还没收到外审邮件，大家有遇到过这种情况吗？最长多久会收到外审邮件啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a452506975, createdName=124af5c7m81暂无昵称, createdTime=Wed Nov 09 21:24:07 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094012, encodeId=ba082094012da, content=22.10.06投稿<br>22.10.10Under Review<br>22.1014收到外审邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5f8299982, createdName=ms2000001702708152, createdTime=Sun Oct 16 10:33:47 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤研究<br>经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894681, encodeId=3b5a89468193, content=要不要版面费，这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Tue Oct 27 01:02:14 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001382, encodeId=1e39100138251, content=请问状态变成under review指送外审了吗？但是没有收到送审的邮件通知呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ddd92153968, createdName=1582019d51m, createdTime=Wed Jul 21 13:09:03 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226137, encodeId=de88122613ec4, content=CR内审和外审都是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b48f5153036, createdName=1663238685_12506575, createdTime=Mon Jun 13 11:29:54 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804355, encodeId=335180435555, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：大家好，问个问题：投稿CR后，会显示一个方法上的Score，这个打分对评审文章有用么？大家都打了多少分？有打4分的么？谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:33:18 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211325, encodeId=b9491211325ab, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：1周多点拒稿，还是很难中的！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11e5109668, createdName=tckkhf2006, createdTime=Fri Apr 15 06:21:02 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969493, encodeId=7d30969493ae, content=期刊质量高，认可度很高。有一篇这个去申国自然青年基本稳中，面上也大概率能过函评。和其他8、9分的期刊像oncogene/cancer letter/Theranostics完全不是一个档次的。<br>大家还是争取发这种高质量期刊申基金才有用，现在内卷严重，评委不是吃素的，看到发的都是oncogene/cancer letter/Theranostics这种期刊基本没戏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Sat May 29 18:16:55 CST 2021, time=2021-05-29, status=1, ipAttribution=)]
    2022-06-13 1663238685_12506575

    CR内审和外审都是Under Review吗

    9

    展开9条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2099486, encodeId=29a3209948625, content=请问各位，最近投稿Cancer research，under review7天了，还没收到外审邮件，大家有遇到过这种情况吗？最长多久会收到外审邮件啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a452506975, createdName=124af5c7m81暂无昵称, createdTime=Wed Nov 09 21:24:07 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094012, encodeId=ba082094012da, content=22.10.06投稿<br>22.10.10Under Review<br>22.1014收到外审邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5f8299982, createdName=ms2000001702708152, createdTime=Sun Oct 16 10:33:47 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤研究<br>经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894681, encodeId=3b5a89468193, content=要不要版面费，这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Tue Oct 27 01:02:14 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001382, encodeId=1e39100138251, content=请问状态变成under review指送外审了吗？但是没有收到送审的邮件通知呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ddd92153968, createdName=1582019d51m, createdTime=Wed Jul 21 13:09:03 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226137, encodeId=de88122613ec4, content=CR内审和外审都是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b48f5153036, createdName=1663238685_12506575, createdTime=Mon Jun 13 11:29:54 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804355, encodeId=335180435555, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：大家好，问个问题：投稿CR后，会显示一个方法上的Score，这个打分对评审文章有用么？大家都打了多少分？有打4分的么？谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:33:18 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211325, encodeId=b9491211325ab, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：1周多点拒稿，还是很难中的！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11e5109668, createdName=tckkhf2006, createdTime=Fri Apr 15 06:21:02 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969493, encodeId=7d30969493ae, content=期刊质量高，认可度很高。有一篇这个去申国自然青年基本稳中，面上也大概率能过函评。和其他8、9分的期刊像oncogene/cancer letter/Theranostics完全不是一个档次的。<br>大家还是争取发这种高质量期刊申基金才有用，现在内卷严重，评委不是吃素的，看到发的都是oncogene/cancer letter/Theranostics这种期刊基本没戏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Sat May 29 18:16:55 CST 2021, time=2021-05-29, status=1, ipAttribution=)]
    2022-10-19 duanbiao127

    为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2099486, encodeId=29a3209948625, content=请问各位，最近投稿Cancer research，under review7天了，还没收到外审邮件，大家有遇到过这种情况吗？最长多久会收到外审邮件啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a452506975, createdName=124af5c7m81暂无昵称, createdTime=Wed Nov 09 21:24:07 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094012, encodeId=ba082094012da, content=22.10.06投稿<br>22.10.10Under Review<br>22.1014收到外审邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5f8299982, createdName=ms2000001702708152, createdTime=Sun Oct 16 10:33:47 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤研究<br>经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894681, encodeId=3b5a89468193, content=要不要版面费，这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Tue Oct 27 01:02:14 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001382, encodeId=1e39100138251, content=请问状态变成under review指送外审了吗？但是没有收到送审的邮件通知呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ddd92153968, createdName=1582019d51m, createdTime=Wed Jul 21 13:09:03 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226137, encodeId=de88122613ec4, content=CR内审和外审都是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b48f5153036, createdName=1663238685_12506575, createdTime=Mon Jun 13 11:29:54 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804355, encodeId=335180435555, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：大家好，问个问题：投稿CR后，会显示一个方法上的Score，这个打分对评审文章有用么？大家都打了多少分？有打4分的么？谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:33:18 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211325, encodeId=b9491211325ab, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：1周多点拒稿，还是很难中的！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11e5109668, createdName=tckkhf2006, createdTime=Fri Apr 15 06:21:02 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969493, encodeId=7d30969493ae, content=期刊质量高，认可度很高。有一篇这个去申国自然青年基本稳中，面上也大概率能过函评。和其他8、9分的期刊像oncogene/cancer letter/Theranostics完全不是一个档次的。<br>大家还是争取发这种高质量期刊申基金才有用，现在内卷严重，评委不是吃素的，看到发的都是oncogene/cancer letter/Theranostics这种期刊基本没戏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Sat May 29 18:16:55 CST 2021, time=2021-05-29, status=1, ipAttribution=)]
    2020-07-24 silent111

    审稿速度:2.0 | 投稿命中率:25.0
    经验分享：大家好，问个问题：投稿CR后，会显示一个方法上的Score，这个打分对评审文章有用么？大家都打了多少分？有打4分的么？谢谢。

    2

    展开2条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2099486, encodeId=29a3209948625, content=请问各位，最近投稿Cancer research，under review7天了，还没收到外审邮件，大家有遇到过这种情况吗？最长多久会收到外审邮件啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a452506975, createdName=124af5c7m81暂无昵称, createdTime=Wed Nov 09 21:24:07 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094012, encodeId=ba082094012da, content=22.10.06投稿<br>22.10.10Under Review<br>22.1014收到外审邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5f8299982, createdName=ms2000001702708152, createdTime=Sun Oct 16 10:33:47 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤研究<br>经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894681, encodeId=3b5a89468193, content=要不要版面费，这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Tue Oct 27 01:02:14 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001382, encodeId=1e39100138251, content=请问状态变成under review指送外审了吗？但是没有收到送审的邮件通知呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ddd92153968, createdName=1582019d51m, createdTime=Wed Jul 21 13:09:03 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226137, encodeId=de88122613ec4, content=CR内审和外审都是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b48f5153036, createdName=1663238685_12506575, createdTime=Mon Jun 13 11:29:54 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804355, encodeId=335180435555, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：大家好，问个问题：投稿CR后，会显示一个方法上的Score，这个打分对评审文章有用么？大家都打了多少分？有打4分的么？谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:33:18 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211325, encodeId=b9491211325ab, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：1周多点拒稿，还是很难中的！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11e5109668, createdName=tckkhf2006, createdTime=Fri Apr 15 06:21:02 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969493, encodeId=7d30969493ae, content=期刊质量高，认可度很高。有一篇这个去申国自然青年基本稳中，面上也大概率能过函评。和其他8、9分的期刊像oncogene/cancer letter/Theranostics完全不是一个档次的。<br>大家还是争取发这种高质量期刊申基金才有用，现在内卷严重，评委不是吃素的，看到发的都是oncogene/cancer letter/Theranostics这种期刊基本没戏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Sat May 29 18:16:55 CST 2021, time=2021-05-29, status=1, ipAttribution=)]
    2022-04-15 tckkhf2006

    审稿速度:2.0 | 投稿命中率:5.0
    经验分享：1周多点拒稿，还是很难中的！

    3

    展开3条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2099486, encodeId=29a3209948625, content=请问各位，最近投稿Cancer research，under review7天了，还没收到外审邮件，大家有遇到过这种情况吗？最长多久会收到外审邮件啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a452506975, createdName=124af5c7m81暂无昵称, createdTime=Wed Nov 09 21:24:07 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094012, encodeId=ba082094012da, content=22.10.06投稿<br>22.10.10Under Review<br>22.1014收到外审邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5f8299982, createdName=ms2000001702708152, createdTime=Sun Oct 16 10:33:47 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤研究<br>经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894681, encodeId=3b5a89468193, content=要不要版面费，这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Tue Oct 27 01:02:14 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001382, encodeId=1e39100138251, content=请问状态变成under review指送外审了吗？但是没有收到送审的邮件通知呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ddd92153968, createdName=1582019d51m, createdTime=Wed Jul 21 13:09:03 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226137, encodeId=de88122613ec4, content=CR内审和外审都是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b48f5153036, createdName=1663238685_12506575, createdTime=Mon Jun 13 11:29:54 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804355, encodeId=335180435555, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：大家好，问个问题：投稿CR后，会显示一个方法上的Score，这个打分对评审文章有用么？大家都打了多少分？有打4分的么？谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:33:18 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211325, encodeId=b9491211325ab, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：1周多点拒稿，还是很难中的！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11e5109668, createdName=tckkhf2006, createdTime=Fri Apr 15 06:21:02 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969493, encodeId=7d30969493ae, content=期刊质量高，认可度很高。有一篇这个去申国自然青年基本稳中，面上也大概率能过函评。和其他8、9分的期刊像oncogene/cancer letter/Theranostics完全不是一个档次的。<br>大家还是争取发这种高质量期刊申基金才有用，现在内卷严重，评委不是吃素的，看到发的都是oncogene/cancer letter/Theranostics这种期刊基本没戏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Sat May 29 18:16:55 CST 2021, time=2021-05-29, status=1, ipAttribution=)]
    2021-05-29 张晓梅-Xiaomei Zhang

    期刊质量高，认可度很高。有一篇这个去申国自然青年基本稳中，面上也大概率能过函评。和其他8、9分的期刊像oncogene/cancer letter/Theranostics完全不是一个档次的。
    大家还是争取发这种高质量期刊申基金才有用，现在内卷严重，评委不是吃素的，看到发的都是oncogene/cancer letter/Theranostics这种期刊基本没戏

    19

    展开19条回复
共376条页码: 3/38页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分